Media stories about G1 THERAPEUTICS (NASDAQ:GTHX) have been trending somewhat positive this week, Accern Sentiment reports. Accern scores the sentiment of press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. G1 THERAPEUTICS earned a media sentiment score of 0.04 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 47.0051667121281 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Shares of G1 THERAPEUTICS (GTHX) opened at 25.72 on Thursday. The company’s 50 day moving average is $15.76 and its 200-day moving average is $16.52. The stock’s market capitalization is $727.49 million. G1 THERAPEUTICS has a 1-year low of $12.04 and a 1-year high of $25.72.

G1 THERAPEUTICS (NASDAQ:GTHX) last released its quarterly earnings results on Wednesday, August 9th. The company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($0.61) by $0.48. Equities analysts anticipate that G1 THERAPEUTICS will post ($2.92) earnings per share for the current fiscal year.

A number of brokerages have issued reports on GTHX. Cowen and Company reiterated a “buy” rating on shares of G1 THERAPEUTICS in a research note on Wednesday, August 9th. Wedbush began coverage on shares of G1 THERAPEUTICS in a research note on Monday, June 12th. They set an “outperform” rating and a $31.00 price target on the stock. Needham & Company LLC began coverage on shares of G1 THERAPEUTICS in a research note on Monday, June 12th. They set a “buy” rating and a $34.00 price target on the stock. Finally, J P Morgan Chase & Co began coverage on shares of G1 THERAPEUTICS in a research note on Monday, June 12th. They set an “overweight” rating and a $23.00 price target on the stock.

ILLEGAL ACTIVITY WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect G1 THERAPEUTICS (GTHX) Stock Price” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The correct version of this article can be read at https://www.thecerbatgem.com/2017/09/07/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-g1-therapeutics-gthx-stock-price.html.

About G1 THERAPEUTICS

G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.

Receive News & Stock Ratings for G1 THERAPEUTICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 THERAPEUTICS and related stocks with our FREE daily email newsletter.